Headline News about Beigene Ltd ADR
4 Analysts Have This to Say About BeiGene
January 20, 2023
Via Benzinga
Via Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
January 20, 2023
Via Benzinga
Via Talk Markets
Via Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
December 12, 2022
Via Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
December 12, 2022
Via Benzinga
Via Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
December 06, 2022
Via Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
September 20, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.